Open AccessComment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136
Author(s) -
Geremia B. Bolli,
Francesca Porcellati,
Paola Lucidi,
Carmine G. Fanelli
Publication year - 2021
Publication title -
diabetes care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.636
H-Index - 363
eISSN - 1935-5548
pISSN - 0149-5992
DOI - 10.2337/dc20-2575
Subject(s) - medicine , diabetic ketoacidosis , insulin , endocrinology , diabetes mellitus , type 1 diabetes , type 2 diabetes , ketoacidosis , dapagliflozin , placebo , alternative medicine , pathology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom